Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

CitraFleet

Phase 3Small molecule

CitraFleet is one of 32 small molecule programs targeting Colonoscopy. It is currently in Phase 3.

2

Indications

3

Total Trials

1

Active Trials

31

Competitors

Pipeline

Status by Indication[3][1]

Indication

ColonoscopyCompleted

Colorectal CarcinomaRecruiting

ColonoscopyPreclinical

Completed

Colorectal CarcinomaPhase 3

Recruiting

Competition

Competitive Landscape

30 competitors in Colorectal Carcinoma

#DrugCompanyPhaseTrials

Verzenio

Stivarga

Tukysa

Avastin

Inlyta

PPrism Pharmaceuticals

Glucophage

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Eloxatin

Tecentriq

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

ApprovedRecruiting

Colorectal Carcinoma

NCT07696793

Clinical

Trials by Indication[1]

Bowel Preparation1 trial

A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)

Completed·NNorgine·Phase 4·NCT01689792·398 enrolled

Colonoscopy1 trial

Evaluation of the Efficacy, Tolerability, and Safety of Two Colonoscopy Preparation Regimens in Children With Inflammatory Bowel Disease: a Randomized Study.

Completed·MMedical University of Warsaw·Preclinical·NCT07786363·125 enrolled

Colorectal Carcinoma1 trial

Efficacy and Tolerability of a Simethicone-containing Evacuating Solution for Colorectal Cancer Screening Colonoscopy: a Randomized Parallel Comparative Trial CLEAN+

Recruiting·FFundacion Clinic per a la Recerca Biomédica·Approved·NCT07696793·818 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for CitraFleet. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CitraFleet compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CitraFleet. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Norgine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNorgine

Related News